Use of high-dose ganciclovir for a resistant cytomegalovirus infection due to UL97 mutation

P. West, M. Schmiedeskamp, H. Neeley, J. Oberholzer, E. Benedetti, B. Kaplan

Research output: Contribution to journalArticle

22 Citations (Scopus)

Abstract

Cytomegalovirus (CMV) infection is a major complication following solid organ transplantation resulting in significant morbidity and mortality. The guidelines published in 2004 have recommendations for therapy; however, the frequency of resistant CMV infection is increasing and therapy is not clearly defined. There are a few alternatives to ganciclovir such as foscarnet, cidofovir, and leflunomide; however, their use is limited by adverse effects. This report summarizes the successful use of high-dose ganciclovir for the treatment of a resistant CMV caused by UL97 mutation.

Original languageEnglish (US)
Pages (from-to)129-132
Number of pages4
JournalTransplant Infectious Disease
Volume10
Issue number2
DOIs
StatePublished - Apr 2008
Externally publishedYes

Fingerprint

Ganciclovir
leflunomide
Cytomegalovirus Infections
Foscarnet
Mutation
Organ Transplantation
Cytomegalovirus
Guidelines
Morbidity
Mortality
Therapeutics
cidofovir

Keywords

  • Cytomegalovirus
  • Ganciclovir
  • Resistance
  • Transplant
  • UL97 mutation

ASJC Scopus subject areas

  • Transplantation
  • Microbiology (medical)
  • Immunology

Cite this

West, P., Schmiedeskamp, M., Neeley, H., Oberholzer, J., Benedetti, E., & Kaplan, B. (2008). Use of high-dose ganciclovir for a resistant cytomegalovirus infection due to UL97 mutation. Transplant Infectious Disease, 10(2), 129-132. https://doi.org/10.1111/j.1399-3062.2007.00249.x

Use of high-dose ganciclovir for a resistant cytomegalovirus infection due to UL97 mutation. / West, P.; Schmiedeskamp, M.; Neeley, H.; Oberholzer, J.; Benedetti, E.; Kaplan, B.

In: Transplant Infectious Disease, Vol. 10, No. 2, 04.2008, p. 129-132.

Research output: Contribution to journalArticle

West, P, Schmiedeskamp, M, Neeley, H, Oberholzer, J, Benedetti, E & Kaplan, B 2008, 'Use of high-dose ganciclovir for a resistant cytomegalovirus infection due to UL97 mutation', Transplant Infectious Disease, vol. 10, no. 2, pp. 129-132. https://doi.org/10.1111/j.1399-3062.2007.00249.x
West, P. ; Schmiedeskamp, M. ; Neeley, H. ; Oberholzer, J. ; Benedetti, E. ; Kaplan, B. / Use of high-dose ganciclovir for a resistant cytomegalovirus infection due to UL97 mutation. In: Transplant Infectious Disease. 2008 ; Vol. 10, No. 2. pp. 129-132.
@article{3bccf8f3d00b49d39cef838abf0c3a32,
title = "Use of high-dose ganciclovir for a resistant cytomegalovirus infection due to UL97 mutation",
abstract = "Cytomegalovirus (CMV) infection is a major complication following solid organ transplantation resulting in significant morbidity and mortality. The guidelines published in 2004 have recommendations for therapy; however, the frequency of resistant CMV infection is increasing and therapy is not clearly defined. There are a few alternatives to ganciclovir such as foscarnet, cidofovir, and leflunomide; however, their use is limited by adverse effects. This report summarizes the successful use of high-dose ganciclovir for the treatment of a resistant CMV caused by UL97 mutation.",
keywords = "Cytomegalovirus, Ganciclovir, Resistance, Transplant, UL97 mutation",
author = "P. West and M. Schmiedeskamp and H. Neeley and J. Oberholzer and E. Benedetti and B. Kaplan",
year = "2008",
month = "4",
doi = "10.1111/j.1399-3062.2007.00249.x",
language = "English (US)",
volume = "10",
pages = "129--132",
journal = "Transplant Infectious Disease",
issn = "1398-2273",
publisher = "Wiley-Blackwell",
number = "2",

}

TY - JOUR

T1 - Use of high-dose ganciclovir for a resistant cytomegalovirus infection due to UL97 mutation

AU - West, P.

AU - Schmiedeskamp, M.

AU - Neeley, H.

AU - Oberholzer, J.

AU - Benedetti, E.

AU - Kaplan, B.

PY - 2008/4

Y1 - 2008/4

N2 - Cytomegalovirus (CMV) infection is a major complication following solid organ transplantation resulting in significant morbidity and mortality. The guidelines published in 2004 have recommendations for therapy; however, the frequency of resistant CMV infection is increasing and therapy is not clearly defined. There are a few alternatives to ganciclovir such as foscarnet, cidofovir, and leflunomide; however, their use is limited by adverse effects. This report summarizes the successful use of high-dose ganciclovir for the treatment of a resistant CMV caused by UL97 mutation.

AB - Cytomegalovirus (CMV) infection is a major complication following solid organ transplantation resulting in significant morbidity and mortality. The guidelines published in 2004 have recommendations for therapy; however, the frequency of resistant CMV infection is increasing and therapy is not clearly defined. There are a few alternatives to ganciclovir such as foscarnet, cidofovir, and leflunomide; however, their use is limited by adverse effects. This report summarizes the successful use of high-dose ganciclovir for the treatment of a resistant CMV caused by UL97 mutation.

KW - Cytomegalovirus

KW - Ganciclovir

KW - Resistance

KW - Transplant

KW - UL97 mutation

UR - http://www.scopus.com/inward/record.url?scp=40849098571&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=40849098571&partnerID=8YFLogxK

U2 - 10.1111/j.1399-3062.2007.00249.x

DO - 10.1111/j.1399-3062.2007.00249.x

M3 - Article

C2 - 17605740

AN - SCOPUS:40849098571

VL - 10

SP - 129

EP - 132

JO - Transplant Infectious Disease

JF - Transplant Infectious Disease

SN - 1398-2273

IS - 2

ER -